Together, these experiments suggested that sCABs efficiently suppressed TNF‐α in the PD mouse brain and significantly ameliorated the symptoms of PD, suggesting that sABs have the potential to be a brain‐targeting delivery carrier for the treatment of central nervous system diseases such as PD. The gene discussed is TNF; the disease is central nervous system disorder.